In allergic asthma, what is the role of short-acting beta-2 agonists (SABA) and what safety considerations apply to frequent use?

• A. SABA provides rapid bronchodilation and symptom relief; overuse can cause tachycardia and tremor, and frequent use may indicate poor controller therapy; review maintenance.
• B. SABA provides anti-inflammatory effect over days.
• C. SABA is used as a long-term controller.
• D. SABA has no adverse effects.

Answer: (C)

Short-acting beta-2 agonists are rescue inhalers that provide rapid relaxation of airway smooth muscle, leading to quick bronchodilation and relief from acute asthma symptoms. They’re meant for immediate symptom relief, not as the daily control strategy. When use becomes frequent, it signals that the underlying inflammation and control are inadequate, so the management plan should shift toward regular controller therapy—typically inhaled corticosteroids, and, if appropriate, additional agents to maintain control.

Safety wise, these medications can cause tachycardia and tremor because they stimulate beta-2 receptors not only in the lungs but also in other tissues. At high doses or with overuse, you can see systemic effects, and relying on them too much can mask worsening asthma and lead to more severe flares. That’s why guidelines emphasize reassessing and adjusting maintenance treatment if rescue inhaler use increases.